Strides Arcolab agrees to receive $150 million as final settlement from Mylan

25 Sep 2014 Evaluate

Strides Arcolab has agreed to receive an amount of $150 million from Mylan Inc., USA as the full and final settlement against the Contingent Holdback of upto $250 million.

Earlier in December 2013, Strides Arcolab completed the sale of its injectables business, Agila Specialties, to Mylan for $1.75 billion, but $250 million of that had been held back by Mylan until certain regulatory conditions related to an injectables facility in India are satisfied.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

793.60 -2.60 (-0.33%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×